Correction to: Scientific Reports 10.1038/s41598-020-67411-w, published online 03 July 2020
The original version of this Article contained an error in the Abstract.
“Preclinical models that reliably recapitulate the immunosuppressive properties of human gliomas are essential to assess immune-based therapies. GL261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become common practice to transfect these cells with luciferase for fluorescent tumor tracking. The aim of this study was to compare the survival of mice injected with fluorescent or non-fluorescent GL261 cells and characterize the differences in their tumor microenvironment.”
now reads:
“Preclinical models that reliably recapitulate the immunosuppressive properties of human gliomas are essential to assess immune-based therapies. GL261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become common practice to transfect these cells with luciferase for bioluminescent tumor tracking. The aim of this study was to compare the survival of mice injected with bioluminescent or non-bioluminescent GL261 cells and characterize the differences in their tumor microenvironment.”
The original Article has been corrected.
Footnotes
The original online version of this Article was revised: The original version of this Article contained an error in the Abstract. “Preclinical models that reliably recapitulate the immunosuppressive properties of human gliomas are essential to assess immune-based therapies. GL261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become common practice to transfect these cells with luciferase for fluorescent tumor tracking. The aim of this study was to compare the survival of mice injected with fluorescent or non-fluorescent GL261 cells and characterize the differences in their tumor microenvironment.” now reads: “Preclinical models that reliably recapitulate the immunosuppressive properties of human gliomas are essential to assess immune-based therapies. GL261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become common practice to transfect these cells with luciferase for bioluminescent tumor tracking. The aim of this study was to compare the survival of mice injected with bioluminescent or non-bioluminescent GL261 cells and characterize the differences in their tumor microenvironment.”.